Adenocarcinoma, Clear Cell - 25 Studies Found
| Active, not recruiting |
: Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer :
|
| Withdrawn |
: Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) :
|
| Completed |
: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer :
|
| Completed |
: Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer :
|
| Completed |
: Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer :
|
| Recruiting |
: Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol :
|
| Not yet recruiting |
: Study to Evaluate Efficacy and Safety of Sunitinib in Patients With Renal Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment : Clear Cell Renal Carcinoma : 2017-02-23 : Drug: Sunitinib Sunitinib 50 mg/d |
| Completed |
: Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer :
|